KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Expenses: 2011-2024

Historic Operating Expenses for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $277.9 million.

  • Esperion Therapeutics' Operating Expenses rose 43.76% to $97.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.2 million, marking a year-over-year increase of 19.42%. This contributed to the annual value of $277.9 million for FY2024, which is 2.21% up from last year.
  • As of FY2024, Esperion Therapeutics' Operating Expenses stood at $277.9 million, which was up 2.21% from $271.9 million recorded in FY2023.
  • Esperion Therapeutics' Operating Expenses' 5-year high stood at $348.9 million during FY2020, with a 5-year trough of $255.0 million in FY2022.
  • Over the past 3 years, Esperion Therapeutics' median Operating Expenses value was $271.9 million (recorded in 2023), while the average stood at $268.3 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 44.51% in 2020, then decreased by 16.45% in 2022.
  • Esperion Therapeutics' Operating Expenses (Yearly) stood at $348.9 million in 2020, then fell by 12.54% to $305.2 million in 2021, then fell by 16.45% to $255.0 million in 2022, then increased by 6.64% to $271.9 million in 2023, then climbed by 2.21% to $277.9 million in 2024.